Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00115219
Status:
COMPLETED
Last Update Posted:
2013-05-30
First Post:
2005-06-21
Brief Title:
Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly BIW in Rheumatoid Arthritis RA Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly QW
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Multi-center Randomized Double-Blind Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly BIW in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly QW
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study objective will be to evaluate the efficacy and safety of etanercept 50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept 50 mg QW and concomitant methotrexate therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None